Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 36; no. 15_suppl; p. TPS8062
Main Authors Rajkumar, S.Vincent, Voorhees, Peter Michael, Goldschmidt, Hartmut, Baker, Ross I., Bandekar, Rajesh, Kuppens, Steven, Neff, Tobias, Qi, Ming, Dimopoulos, Meletios A.
Format Journal Article
LanguageEnglish
Published 20.05.2018
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.2018.36.15_suppl.TPS8062